CompletedPhase 1NCT00000778
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
Studying Primary genito-urinary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Hafner R, M.D
- Intervention
- Isoniazid(drug)
- Enrollment
- 44 enrolled
- Eligibility
- 18 years · All sexes
Study locations (10)
- Univ of Alabama at Birmingham, Birmingham, Alabama, United States
- UCLA Med Ctr, Los Angeles, California, United States
- Harbor - UCLA Med Ctr, Torrance, California, United States
- Broward Gen Med Ctr, Fort Lauderdale, Florida, United States
- Univ of Miami / Jackson Memorial Hosp, Miami, Florida, United States
- Univ of Illinois, Chicago, Illinois, United States
- Tulane Univ Med School, New Orleans, Louisiana, United States
- Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
- Univ TX Galveston, Galveston, Texas, United States
- Baylor College of Medicine / Houston Veterans Adm Med Ctr, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00000778 on ClinicalTrials.govOther trials for Primary genito-urinary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05917210Peer-led Implementation of TB-HIV Education and Adherence Counseling in UgandaYale University
- RECRUITINGNCT07312266Questioning the Epidemiology of Asymptomatic TBBarcelona Institute for Global Health
- RECRUITINGNANCT05842161South Africa Smoking Cessation and Engagement in HIV/TB Care CareMassachusetts General Hospital
- RECRUITINGPHASE3NCT05575518A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary TuberculosisStellah Mpagama
- ACTIVE NOT RECRUITINGPHASE4NCT05118490Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis PatientsThe Aurum Institute NPC
- RECRUITINGNANCT05342064Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered ServiceBaylor College of Medicine